The US Department of Justice (DOJ) has announced it will ease federal restrictions on certain cannabis products and begin reclassifying marijuana as a less dangerous substance, marking a major shift in US drug policy.
Acting Attorney General Todd Blanche said state-regulated medical cannabis would move from Schedule I to a lower classification alongside substances such as ketamine and some painkillers. The DOJ will begin formal proceedings on 29 June to gather evidence on broader rescheduling.
The change follows a December 2025 executive order from President Donald Trump and could reduce research barriers, tax burdens, and funding restrictions across the $47bn cannabis industry.
- Medical cannabis to be moved to lower-risk classification
- Federal rescheduling process to begin 29 June
- US cannabis sales forecast to exceed $47bn in 2026
“Today marks a pivotal moment for the United States. With President Trump’s action to reschedule cannabis, federal policy is finally aligning with science, medicine, and most importantly, patient needs,” said Irwin Simon, CEO of marijuana company Tilray Brands
Shares of cannabis firms rose 6–13% after the announcement. Critics warn of potential risks including youth access and road safety impacts.
ℹ️ Reuters
Follow on social media TikTok@tut0ughInstagram@tut0ugh Threads@tut0ugh X@tut0ugh YouTube@tut0ugh
tut0ugh 